Perspectives by the Leerink Center for Pharmacoeconomics

Perspectives by the Leerink Center for Pharmacoeconomics

Leerink Partners
Country USA
Language EN
Episodes 2
Latest 04.11.2026

Perspectives is a podcast series from the Leerink Center for Pharmacoeconomics, hosted by Dr. Mel Whittington. It features conversations with industry experts to explore the societal impact of healthcare innovations.

Episodes

  • How Are JCA and the EU Pharma Package Changing the Economics of Drug Development? A Perspective from Graham Cookson
    How Are JCA and the EU Pharma Package Changing the Economics of Drug Development? A Perspective from Graham Cookson 04.11.2026 37m
    What do Europe’s changing pharmaceutical policies mean for the economics of drug development? In this episode of Perspectives, Mel Whittington speaks with Graham Cookson, CEO of the Office of Health Economics, to discuss three major developments impacting the European life sciences landscape: joint clinical assessment (JCA), the EU Pharma Package, and most-favored-nation (MFN) pricing. Graham explains how JCA impacts the way comparative clinical evidence is generated and assessed across Europe and the importance of planning for it before pivotal trials are designed. He also gets into how the E...
  • How Does 340B Impact the Economics of a Drug? A 340B 101 with Sabrina Aery
    How Does 340B Impact the Economics of a Drug? A 340B 101 with Sabrina Aery 07.10.2026 50m
    Sabrina Aery, a 340B expert with more than 30 years of experience across hospitals, health plans, pharmaceutical manufacturers, and consulting, joins Perspectives to provide a 340B 101. She discusses the foundations of the program, how it works in practice, and how the program layers into the broader pharmaceutical pricing system. The episode concludes by discussing how the 340B program can impact the economics of a prescription drug and what biotech investors and executives can consider when evaluating potential 340B exposure. Topics discussed include: Who qualifies as a 340B covered entity a...
  • How Do WAC, AMP, ASP, 340B, and MFP Fit Together? A Branded Drug Pricing 101 with Inma Hernandez
    How Do WAC, AMP, ASP, 340B, and MFP Fit Together? A Branded Drug Pricing 101 with Inma Hernandez 31.08.2026 1h 4m
    Inma Hernandez, PharmD, PhD, Senior Advisor for Drug Prices at the Centers for Medicare and Medicaid Services, joins Perspectives to give an overview of drug pricing regulatory dynamics for branded drugs in the US. The episode is a step-by-step walkthrough of the different prices a branded drug can have in the U.S. and how those prices are established across commercial insurance, Medicaid, Medicare Part B, and Medicare Part D. Inma explains the alphabet soup of WAC, AMP, best price, ASP, and MFP; how rebates and statutory discounts translate list prices into the net prices realized by innovato...
  • Can Health Economics Lead to Better Biotech? A Conversation with Rob Abbott
    Can Health Economics Lead to Better Biotech? A Conversation with Rob Abbott 03.08.2026 43m
    Rob Abbott, CEO of ISPOR, joins Perspectives to talk about why health economics and outcomes research (HEOR) has become more relevant for biotech founders, executives, and investors. The conversation challenges the common perception that HEOR is primarily a post-approval exercise used to support pricing and reimbursement. Instead, Rob discusses how evidence generation, economic modeling, and value strategy can shape clinical development, inform investment decisions, and strengthen the commercial potential of new therapies. The episode concludes with a discussion of ISPOR's Healthcare Investmen...
  • What Happens When Drug Pricing Meets Trade Policy? A Conversation with Ron Lanton
    What Happens When Drug Pricing Meets Trade Policy? A Conversation with Ron Lanton 08.07.2026 45m
    Ron Lanton, the Founder and President of Lanton Strategies International, joins Perspectives by the Leerink Center for Pharmacoeconomics to discuss the use of trade mechanisms to address pharmaceutical pricing. Ron provides insight into the growing intersection of pharmaceutical pricing and international trade policy, why recent developments could be significant, and what it could mean for biopharmaceutical companies, investors, and patients. Topics discussed include: U.S. Trade Representative’s recent Section 301 investigation into Germany’s drug pricing and reimbursement practices U.S.-U.K....
  • Can Clinical Trial Failure Be Insured? A Conversation with Tomas Philipson
    Can Clinical Trial Failure Be Insured? A Conversation with Tomas Philipson 08.06.2026 45m
    Dr. Tomas Philipson, former Acting Chairman of the White House Council of Economic Advisers and Professor Emeritus at the University of Chicago, joins Perspectives by the Leerink Center for Pharmacoeconomics to discuss a new insurance model he developed that insures biotech investments against clinical trial failure. He explains how this insurance could reshape the way risk is managed in life sciences innovation and could expand access to capital for biotech. The second half of the episode turns to drug pricing policy where Philipson shares his perspectives on current and proposed reforms. Top...
  • Are We Pricing Drugs Right? A Conversation with Peter Neumann on How Innovation is Valued Globally
    Are We Pricing Drugs Right? A Conversation with Peter Neumann on How Innovation is Valued Globally 08.06.2026 46m
    In this episode of Perspectives by the Leerink Center for Pharmacoeconomics, host Mel Whittington sits down with renowned health economist Dr. Peter Neumann following the annual meeting of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center. Drawing from conversations that took place at the meeting, Mel and Peter explore some of the questions that are shaping how innovation is valued globally. The discussion covers: Whether cost-effectiveness analysis captures all the factors that are considered when pricing a drug How payers use outcomes assessments to sha...
  • What’s Behind Drug Pricing: The Hidden Role and Limits of Cost-Effectiveness Analysis
    What’s Behind Drug Pricing: The Hidden Role and Limits of Cost-Effectiveness Analysis 02.06.2026 39m
    In this episode of Perspectives by the Leerink Center for Pharmacoeconomics, Melanie Whittington breaks down a fundamental—and increasingly consequential—question in health economics: what counts as value in cost-effectiveness analysis? For biotech leaders and investors, Mel cautions that this isn’t just an academic debate. The frameworks adopted by HTA bodies influence pricing, access, and ultimately, how innovation is rewarded. In this episode, Mel explores: The evolution of perspective in cost-effectiveness analysis Why CEA is not a “precise” science—and why that matters How modeling choice...
  • Welcome to Perspectives by the Leerink Center for Pharmacoeconomics
    Welcome to Perspectives by the Leerink Center for Pharmacoeconomics 29.05.2026
    In our signature podcast series, Dr. Mel Whittington, a health economist and Head of the Leerink Center for Pharmacoeconomics, talks with people from across the industry to hear their stories and to better understand the societal impact of healthcare innovations. If you’re interested in participating in future podcasts or would like to learn more about the Leerink Center for Pharmacoeconomics, please email cpe@medacorp.com.

Popular in

The podcast also appears in the podcast charts of these countries.